Effects on atrial fibrillation in aged hypertensive rats by Ca(2+)-activated K(+) channel inhibition

Jonas G Diness1, Lasse Skibsbye, Thomas Jespersen

  • 1NeuroSearch A/S, Pederstrupvej 93, 2750 Ballerup, Denmark.

Insights

Inhibition of small conductance Ca(2+)-activated K(+) (SK) channels using NS8593 and UCL1684 demonstrated antiarrhythmic effects in a rat model of atrial fibrillation (AF) with hypertension. These SK channel inhibitors effectively increased the atrial refractory period and reduced AF duration.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Electrophysiology

Background:

  • Small conductance Ca(2+)-activated K(+) (SK) channel inhibition shows antiarrhythmic potential in acute atrial fibrillation (AF) models.
  • Existing models do not fully represent AF's complexity, particularly the role of hypertension and atrial remodeling.

Purpose of the Study:

  • To evaluate the antiarrhythmic efficacy of SK channel inhibitors (NS8593, UCL1684) in aging, spontaneously hypertensive rats with hypertension-induced atrial remodeling.
  • To assess the impact of these inhibitors on atrial electrophysiology and AF vulnerability in a relevant preclinical model.

Main Methods:

  • Aging spontaneously hypertensive rats and normotensive Wistar-Kyoto rats (3, 8, 11 months) were treated with NS8593, UCL1684, or vehicle.
  • Open-chest in vivo experiments included burst pacing to induce AF and measurements of atrial effective refractory period (AERP).

Main Results:

  • Aging hypertensive rats exhibited increased vulnerability to AF induction.
  • SK channel inhibition with NS8593 and UCL1684 significantly prolonged the AERP and reduced AF duration in both rat strains.
  • The antiarrhythmic efficacy of SK channel inhibitors remained consistent across different ages.

Conclusions:

  • SK channel inhibition with NS8593 and UCL1684 exhibits significant antiarrhythmic properties in a rat model of paroxysmal AF associated with hypertension-induced atrial remodeling.
  • These findings support SK channels as a promising therapeutic target for AF treatment, even in the presence of underlying hypertension.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...